

## Mandated, Highly Recommended, and Other Vaccines for Oral Healthcare Personnel



**Course Author(s):** Michael A. Huber, DDS; Denise Kissell, BSDH, EFDA, MPH; Geza T. Terezhalmay, DDS, MA

**CE Credits:** 2 hours

**Intended Audience:** Dentists, Dental Hygienists, Dental Assistants, Dental Students, Dental Hygiene Students, Dental Assistant Students

**Date Course Online:** 05/29/2015

**Last Revision Date:** 07/20/2024

**Course Expiration Date:** 07/19/2027

**Cost:** Free

**Method:** Self-instructional

**AGD Subject Code(s):** 148

**Online Course:** [www.dentalcare.com/en-us/ce-courses/ce479](http://www.dentalcare.com/en-us/ce-courses/ce479)

### Disclaimers:

- P&G is providing these resource materials to dental professionals. We do not own this content nor are we responsible for any material herein.
- Participants must always be aware of the hazards of using limited knowledge in integrating new techniques or procedures into their practice. Only sound evidence-based dentistry should be used in patient therapy.

### Conflict of Interest Disclosure Statement

- Dr. Huber is a member of the dentalcare.com Advisory Board. He has no relevant financial relationships to disclose.
- Ms. Kissell reports no conflicts of interest associated with this course. She has no relevant financial relationships to disclose.
- Dr. Terézhalmy has done consulting work for Procter & Gamble and has served on the dentalcare.com Advisory Board. He has no relevant financial relationships to disclose.

### Short Description – Forensic Dentistry

Mandated, Highly Recommended, and Other Vaccines for Oral Healthcare Personnel is a free dental continuing education course that covers a wide range of topics relevant to the oral healthcare professional community.

## Course Contents

- Overview
- Learning Objectives
- Introduction
- Vaccine Characterization
- Immunoglobulins
- Vaccine Safety and Adverse Effects
  - Live Attenuated versus Inactivated Vaccines
  - Allergic Reactions
  - Administration-related Problems
- Mandated, Highly Recommended, and Other Vaccines
  - Hepatitis B Infections
  - Influenza
  - Measles, Mumps, and Rubella
  - Varicella and Herpes Zoster Infections
  - Tetanus, Diphtheria, and Pertussis
  - HPV Infection
  - SARS-CoV-2
  - Meningococcal Disease
  - Pneumococcal Disease
  - Hepatitis A Viral Infection
- Documenting Immunization Compliance
- Summary
- Course Test
- References
- About the Authors

## Overview

Immunization strategies for oral healthcare personnel (OHCP) are predicated on (1) vaccines mandated or strongly recommended at the time of employment, (2) vaccines recommended for adults in general, and (3) vaccines recommended when other risk factors (other than occupation) are also present. This course presents current knowledge related to vaccination strategies in healthcare settings is supported by data derived from well-conducted trials or extensive, controlled observations, or, in the absence of such data, by best-informed, most authoritative opinions available.

### **Syllabus: Infection Prevention, Hazardous Waste Management, and Hazard Communication Compliance**

The information in this 13-module syllabus is intended (1) to meet initial educational/training requirements for Dental Students, Dental Hygiene Students, and Dental Assistant Students as mandated by OSHA and

other federal, state, local and professional organizations, (2) to provide a framework for an in-service training program in oral healthcare settings to meet annual educational/training requirements as mandated by OSHA and other federal, state, local and professional organizations, and (3) to serve as a resource for oral healthcare personnel wishing to review evidence-based information on specific topics related to infection prevention, hazardous waste management, and hazard communication compliance. [LEARN MORE](#)

## Learning Objectives

**Upon completion of this course, the dental professional should be able to:**

- Discuss the pharmacology of immunobiologicals.
- Discuss vaccine safety and adverse effects.
- Identify vaccine-preventable diseases.
- Develop vaccination strategies appropriate for the oral healthcare setting.
- Discuss strategies to determine and document evidence of immunity to vaccine-preventable diseases.

## Introduction

Immunization programs in the United States have markedly reduced the incidence of vaccine-preventable diseases in children. Today, a substantial percentage of the remaining morbidity and mortality from several of these diseases occurs in older adolescents and adults who escaped natural infection or immunization during childhood and who are now at increased risk of these diseases because of lifestyle, advanced age, the presence of certain chronic diseases, or occupation (e.g., healthcare workers).<sup>1-3</sup> Other vaccine-preventable diseases primarily affect persons older than 20 years of age; for these diseases, the targeted risk groups for immunization are predictably adults.<sup>4</sup>

The Occupational Safety and Health Administration's final rule regarding bloodborne pathogens mandates that all OHCP who may be exposed to blood or other potentially infectious material (OPIM) in an occupational setting be vaccinated against the hepatitis B virus.<sup>5</sup> Furthermore, the Advisory Committee on Immunization Practices (ACIP) highly

recommends routine vaccination against influenza, varicella, zoster, measles/mumps/rubella, tetanus-diphtheria, pertussis, and the human papillomavirus (HPV).<sup>4,6</sup> The vaccination of OHCP against meningococcus, pneumococcus, and the hepatitis A virus are recommended under special circumstances.<sup>4,6</sup>

The Occupational Safety and Health Administration's final rule regarding bloodborne pathogens mandates that all OHCP who may be exposed to blood or other potentially infectious material (OPIM) in an occupational setting be vaccinated against the hepatitis B virus.<sup>5</sup> Furthermore, the Advisory Committee on Immunization Practices (ACIP) highly recommends routine vaccination against influenza, varicella, zoster, measles/mumps/rubella, tetanus-diphtheria, pertussis, and the human papillomavirus (HPV).<sup>4,6</sup> The vaccination of OHCP against meningococcus, pneumococcus, and the hepatitis A virus are recommended under special circumstances.<sup>4,6</sup>

### Vaccine Characterization

Vaccines may be categorized as whole-pathogen vaccines, subunit vaccines, or nucleic acid vaccines.<sup>7</sup> Whole-pathogen vaccines consist of either live attenuated or inactivated microorganisms. Live attenuated vaccines use a weakened form of the pathogen, which after administration replicates and induces an immune response.

Subunit vaccines are prepared from fractional antigenic components of an organism and may be protein-based, pure polysaccharide-based, conjugate polysaccharide-based, or

recombinant protein-based.<sup>7</sup> Subunit vaccines typically incorporate adjuvants (e.g., alum, AS04, AS01B, others) to generate a stronger immune response because subunit vaccines alone are not effective in inducing adequate long-term immunity.<sup>8</sup>

Nucleic acid vaccines (e.g., mRNA vaccines, DNA plasmid vaccines, recombinant vector vaccines) introduce the specific genetic material encoding the target antigen or antigens against which an immune response is sought.<sup>7</sup> Once introduced, the body's own cells then use the genetic material to produce the antigens. Potential advantages of this approach include no risk of infection; improved vaccine stability; stimulation of broad long-term immunity; and rapid, inexpensive, and scalable vaccine manufacturing.<sup>9</sup>

All vaccines initiate immune responses mediated by macrophages and lymphocytes, i.e., they induce active immunity. Antibodies are produced against specific infective agents or their toxins. Protective antibodies, which may be produced in response to vaccines and their mechanisms of action, are listed in Box 1.<sup>10</sup>

Neutralizing antibodies cannot readily diffuse into infected cells; they must interact with the target-organism before initial intracellular penetration. Immunization with live attenuated organisms is more predictable than immunization with inactivated microorganisms in inducing long-term immunity.<sup>7</sup>

#### Box 1. Protective Antibodies and their Mechanisms of Action.<sup>10</sup>

Antitoxins	Inactivate toxic microbial protein products
Opsinins	Facilitate phagocytosis of microorganisms
Lysins	Damage microbial cell membrane
Antiadhesins	Prevent adhesion of microorganisms to host cell components
Neutralizing antibodies	Prevent the proliferation of microorganisms

Immunogenic responses to live attenuated and inactivated microorganisms develop more slowly than the incubation period of most pathogens. Therefore, vaccines must be administered prior to exposure to a specific etiologic agent. By contrast, “booster” re-immunization in a previously immune individual provides a rapid secondary (anamnestic) increase in immunity. The persistence of immunity may also be prompted by natural re-exposure to microorganisms and the presence of latent infections.

### Immunoglobulins

Immunoglobulins (IGs), predominantly IgG antibodies, may be obtained from human or animal donors who have recovered from an infectious disease or who have been previously immunized.<sup>11</sup> IGs provide immediate, short-term protection, i.e., passive immunity, for those who might develop infection before a vaccine could induce active immunity. Passive immunity is also useful when a vaccine is unavailable or contraindicated, or when an individual cannot produce antibodies.<sup>11</sup>

### Vaccine Safety and Adverse Effects

The National Childhood Vaccine Injury Act of 1986 requires that healthcare providers report to the United States Department of Health and Human Services post-immunization events serious enough to require medical attention.<sup>12</sup> Based on all available data, vaccines licensed in the U.S. are remarkably safe and effective.

### Live Attenuated versus Inactivated Vaccines

Compared to inactivated vaccines, live attenuated vaccines tend to have higher rates of adverse effects (particularly fever).<sup>13</sup> Potentially, vaccines containing live attenuated viruses can also infect the fetus. Vaccines containing live attenuated viruses should only be administered to pregnant women if there is a high immediate risk of infection by a specific pathogen, e.g., a poliomyelitis epidemic. The same precaution applies to individuals with a compromised immune system (Box 2).

### Allergic Reactions

In addition to the desired antigen, live attenuated and inactivated vaccines almost always contain other components such

### Box 2. Contraindications to the Administration of Vaccines Containing Live-attenuated Viruses.<sup>113</sup>

- Individuals receiving cancer chemotherapy
- Organ transplant recipients
- Corticosteroid therapy
- Known or suspected congenital or acquired defects in cell-mediated immunity
  - Severe congenital immunodeficiency disease
  - Leukemia
  - Lymphoma
  - Hodgkin’s disease
  - Acquired immunodeficiency syndrome

as residual animal or human proteins, antibacterial agents, and preservatives or stabilizers, which may cause allergic reactions. The most common allergenic component of vaccines is egg protein found in vaccines prepared in chicken eggs or chicken embryonic cultures, e.g., measles, mumps, and influenza.

Egg allergy is very common, affecting 1 to 2 percent of children.<sup>14,15</sup> However, with the exception of those with a high titer of egg IgE antibodies, most children are likely to develop egg tolerance by late childhood.<sup>16</sup> Adults who can eat eggs or egg-containing products can receive these vaccines safely. On rare occasions, patients will have an anaphylactic reaction to baker’s yeast found in HBV vaccines and to neomycin found in trace amounts in the measles, mumps, rubella, and varicella vaccines.

### Administration-related Problems

The recommended route of administration and dosages for each vaccine are specified on package inserts. Most vaccines for adults are given by subcutaneous (SC) or intramuscular (IM) injection. When administering vaccines, it is imperative to aspirate before depressing the plunger to make certain that the product is not injected intravenously. Intravascular injection can result in increased adverse effects and may also reduce the immune response.

It is also important that a needle 1-1.5 inches long be used for IM delivery of vaccines containing

aluminum phosphate (e.g., HBV, Td, and Tdap vaccines). Subcutaneous administration of such vaccines can lead to local tissue necrosis. Intramuscular injections should be given in the deltoid muscle. Studies with the hepatitis B vaccine have shown that its immunogenicity is significantly reduced when given in the buttocks.<sup>17</sup> This observation may apply to other vaccines as well.

### Mandated, Highly Recommended, and Other Vaccines

Immunization strategies (active and passive) for OHCP are predicated on:

1. vaccines mandated or strongly recommended at the time of employment,
2. vaccines recommended if another risk factor is present, and
3. the availability of immunoglobulins, which are administered to susceptible persons in the event of inadvertent exposure to blood or OPIM.

### Hepatitis B Infections

HB viral infection remains a major vaccine-preventable health hazard for OHCP.<sup>18,19</sup> The virus is transmitted primarily through contact with blood and OPIM (also sexual contact and perinatal exposure).<sup>19</sup> Acute infection is characterized by anorexia, nausea, vomiting, malaise, and fever. After 3 to 10 days, the urine darkens. Jaundice, if present, usually peaks in 1-2 weeks and fades during a 2- to 4-week recovery phase. Following acute infection, up to 10% of those infected become chronic carriers. They may be asymptomatic or develop chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma.<sup>18,19</sup>

### Active Immunization: HBV Vaccines<sup>4,6</sup>

It is mandated that all OHCP be vaccinated against the HBV. Among OHCP, the risks for percutaneous and permucosal exposures to blood vary during training and work career of each person, but the risks are highest during the professional training period. Therefore, vaccination should be completed during training. Those who decline the hepatitis B vaccination series must sign a copy of the Mandatory Hepatitis B Vaccination Declination Form (Box 3).<sup>5</sup>

Hepatitis B vaccines (Table 1) contain hepatitis B surface antigen (HBsAg) protein grown in baker's yeast using recombinant DNA technology. It is subsequently purified and adsorbed to aluminum hydroxide. Primary immunization with hepatitis B vaccine consists of two or three IM doses. The deltoid muscle is the preferred site for adolescent and adult patients because injections given into the buttocks yield lower seroconversion rates.<sup>17</sup>

While pre-vaccination serologic screening for previous HBV infection is not indicated for persons being vaccinated because of occupational risk, post-vaccination confirmation of seroconversion is strongly recommended 1-2 months after the 3rd dose (Box 4).

It is well-established that over time the HBsAb titer falls, often below the currently accepted threshold value of 10 mIU/mL. However, there is no evidence that vaccinated persons lose their immunity simply because the anti-HBsAb titer drops below the arbitrary threshold. Currently, the U.S. Public Health Service does not recommend routine booster doses of the hepatitis B vaccine.<sup>21</sup>

### Box 3. Mandatory Hepatitis B Vaccination Declination Form<sup>5</sup>

I understand that due to my occupational exposure to blood or other potentially infectious materials I may be at risk of acquiring Hepatitis B virus (HBV) infection. I have been given the opportunity to be vaccinated with Hepatitis B vaccine, at no charge to myself. However, I decline Hepatitis B vaccination at this time. I understand that by declining this vaccine, I continue to be at risk of acquiring Hepatitis B, a serious disease. If in the future I continue to have occupational exposure to blood or other potentially infectious materials and I want to be vaccinated with Hepatitis B vaccine, I can receive the vaccination series at no charge to me.

\_\_\_\_\_  
Employee Signature

\_\_\_\_\_  
Date

**Table 1.** HBV Vaccines for Adolescents and Adults.<sup>20</sup>

Vaccines	Indications	Schedules	Adverse Effects
<i>Engerix-B</i>	Preexposure	3 IM doses at 0, 1, and 6 months	Pain at injection site (most common); fever; anaphylaxis in persons with history of allergic reaction to baker's yeast.
<i>Recombivax-HB</i>	Preexposure	3 IM doses at 0, 1, and 6 months	Pain at injection site (most common); systemic effect, anaphylaxis in persons with history of allergic reaction to baker's yeast or latex.
<i>Heplisav-B</i>	Preexposure	2 IM doses at 0 and 1 month	Pain at injection site (most common); fever; anaphylaxis in persons with history of allergic reaction to baker's yeast.
<i>PreHevbrio</i>	Preexposure	3 IM doses at 0, 1 and 6 months	Pain at injection site (most common), headache, fatigue, myalgia.
<i>Twinrix</i>	Preexposure	3 IM doses at 0, 1 and 6 months OR Accelerated 4 dose schedule of 0, day 7, day 21-30 and booster at 12 months	Pain at injection site (most common), redness, headache, fatigue, anaphylaxis in persons with history of allergic reaction to yeast or neomycin.
<i>Engerix-B</i>	Postexposure	4 IM doses at 0, 1, 2 and 12 months	Pain at injection site (most common); fever; anaphylaxis in persons with history of allergic reaction to baker's yeast.

**Box 4.** Post-vaccination Confirmation of Seroconversion<sup>6,21</sup>

1. Post-vaccination confirmation of seroconversion is strongly recommended 1-2 months after the final dose.
  - a. A HBsAb titer >10 mIU/mL is considered adequate
2. OHCP who do not develop an adequate antibody response to the primary vaccine series shall undergo a second 2 or 3-dose vaccine series.
  - a. Retesting for HBsAb is strongly recommended 1-2 months after the 3rd dose of the second vaccine series.
    - If no antibody response occurs, testing for HBsAg is strongly recommended.
      - Those who are HBsAg-negative shall be counseled about precautions to prevent HBV infection and the need to obtain HBIG prophylaxis for any known or probable parenteral exposure to HBsAg-positive blood.
      - Those who are HBsAg-positive shall be counseled about how to prevent the transmission of HBV to others and about the need for medical consultation.

## Passive Immunization: Hepatitis B Immune Globulin<sup>4,6</sup>

OHCP who either declined vaccination or failed to seroconvert are at risk of HBV infection. Hepatitis B immune globulin (HBIG), if administered within 1 week of exposure (ideally within 24 hours), is 75% effective in preventing infection. In addition to HBIG prophylaxis, an alternate 4-dose series of the vaccine should also be offered to those who in the past declined the vaccine (see Table 1). If the person chooses not to take the vaccine, a second dose for HBIG should be administered 30 days after the first dose.

## Influenza

Human influenza is caused by two influenza viruses, types A and B. They are spread by airborne droplets generated when an infected person coughs and sneezes, by direct contact with nasal or throat secretions of infected persons, and less frequently by freshly contaminated articles. Uncomplicated influenza is characterized by the abrupt onset of fever, myalgia, headache, nonproductive cough, sore throat, and rhinitis. Complications include secondary bacterial sinusitis and otitis, and primary viral and secondary bacterial pneumonia.<sup>22</sup>

## Active Immunization: Influenza Vaccines<sup>4,6,23</sup>

It is strongly recommended that all OHCP, including those in training, be vaccinated annually against influenza. Vaccination not only protects the provider, but very likely reduces the risk of healthcare-associated transmission. Each year one or more virus strains in the vaccine might change on the basis of global surveillance and the emergence and spread of new strains. For example, the seasonal influenza vaccines for the 2023–24 season were quadrivalent, containing hemagglutinin (HA) derived from influenza A(H1N1)pdm09 virus, influenza A(H3N2) virus, influenza B/Victoria lineage virus, and influenza B/Yamagata lineage virus.<sup>23</sup>

Three types of influenza vaccines are available in the U.S.: multiple inactivated influenza vaccines (IIVs) one recombinant influenza vaccine (RIV), and one live attenuated influenza vaccine (Table 2).<sup>23</sup> The live attenuated intranasal vaccine (Flumist™) is approved for use by healthy persons between the ages of 19-49 years. OHCP who choose to use Flumist™ in lieu of an inactivated influenza vaccine should refrain from contact with immunosuppressed persons for 7 days. Two IIVs are specifically formulated for patients ≥65 years of age. It is recommended that all individuals over 6 months, who do not have a contraindication, receive an influenza vaccine, including those with an egg allergy.<sup>23</sup>

**Table 2.** Influenza Vaccines.<sup>24</sup>

Vaccine Type	Vaccines	Schedules	Adverse Effects
IIV4	Afluria Quadrivalent Fluarix Quadrivalent FluLaval Quadrivalent Fluzone Quadrivalent Flucelvax Quadrivalent * Fluzone High-Dose Quadrivalent Fluad Quadrivalent Fluad	1 IM dose annually	Pain at injection site (most common); fever; anaphylaxis in persons with history of allergic reaction to baker's yeast.
RIV4	Flublok Quadrivalent †	1 IM dose annually	Pain at injection site (most common); fever; anaphylaxis in persons with history of allergic reaction to baker's yeast.
LAIV4	Flumist Quadrivalent	1 intranasal dose annually	Mild rhinorrhea, nasal congestion, and sore throat; may exacerbate asthma; anaphylaxis in persons with history of allergic reaction to egg.
* cell culture-based			
† recombinant, egg-free			

### Antiviral Chemoprophylaxis: Antiviral Agents

Four antiviral agents are available to reduce influenza duration and the risk of complications such as pneumonia, respiratory failure and death. These include the neuraminidase inhibitors (oral oseltamivir [Tamiflu], inhaled zanamivir [Relenza], IV peramivir [Rapivab]) and the oral polymerase acidic endonuclease inhibitor baloxavir [Xofluza]. All of these agents are active against influenza A and B viruses and are most effective if initiated within 48 hours of the onset of symptoms.<sup>25</sup> The use of oseltamivir or zanamivir within 48 hours before, peramivir within 5 days before, or baloxavir within 17 days before administration of the live-attenuated intranasal influenza vaccine (FluMist Quadrivalent) could inhibit replication of the vaccine virus, reducing the vaccine's effectiveness, and is not recommended.<sup>25</sup>

### Measles, Mumps, and Rubella

The measles virus is spread by airborne droplets, direct contact with nasal or throat secretions of infected persons, and less frequently by freshly contaminated articles. It is one of the most contagious infectious diseases. Following an incubation period of 7 to 18 days, the infected person experiences a prodrome of malaise, fever, coryza, and conjunctivitis before a generalized rash appears. The period of communicability is from the beginning of the prodromal period to about 4 days after the appearance of the rash.<sup>26</sup>

The mumps virus spreads by airborne droplets and direct contact with saliva of infected persons. It has an incubation period of 12 to 25 days, and the virus may be shed into saliva 6 to 7 days before the onset of clinical illness and up to 9 days after. Mumps characterized by acute onset of unilateral or bilateral tender swelling

of the parotid and/or other salivary glands. It is typically self-limiting and lasts an average of five days. In the United States, a substantial number of mumps cases occur among adults 18-25 years old.<sup>27</sup>

The rubella (German measles) virus is transmitted by airborne droplets and direct contact with nasopharyngeal secretions. An incubation period of about 18 days is followed by fever, conjunctivitis, lymphadenopathy, a generalized maculopapular rash, arthralgia, and arthritis. The period of communicability is from 7 days before to 7 days after the onset of rash. Congenital rubella syndrome in the U.S. is rare, but immunity in women of childbearing age remains a special concern.<sup>28</sup>

### Active Immunization: Measles, Mumps, and Rubella Vaccines<sup>4,6</sup>

It is strongly recommended that OHCP be immune to measles, mumps, and rubella. OHCP are considered immune only if they have documentation of:

1. physician-diagnosed measles, mumps, or rubella infection, or
2. laboratory evidence of measles, mumps, or rubella immunity, or
3. appropriate vaccination against measles, mumps, and rubella.

While separate monovalent formulation vaccines for measles, mumps, and rubella are available, the trivalent MMR vaccine (Table 3) is the vaccine of choice for routine adult vaccination. The MMR vaccine contains live attenuated measles and mumps virus grown in chick embryo and live attenuated rubella virus grown in human diploid cell culture. There is no evidence to support a causal association between the MMR vaccine and autism.<sup>29,30</sup>

**Table 3.** Measles, Mumps and Rubella Vaccine.<sup>26-28</sup>

Vaccines	Indications	Schedules	Adverse Effects
<i>MMR II</i>	Preexposure	2 SC doses 28 days apart	Pain and erythema at the site of injection (7-29%); transient arthralgia (25%); fever and rash (5%); anaphylaxis in persons with history of allergic reaction to egg, neomycin, or gelatin.
<i>Priorix</i>	Preexposure	2 SC doses 3-5 years apart	Pain and erythema at the site of injection.



**Varicella and Herpes Zoster Infections**

The *varicella zoster* virus (VZV) is a highly contagious disease transmitted from person-to-person by airborne droplets; contact with vesicular fluid, skin and mucous membranes; and freshly contaminated articles. The VZV is responsible for both chickenpox and herpes zoster (HZ) infections, also known as shingles. Following initial exposure, after an incubation period of 10-21 days the patient develops a generalized papulovesicular rash which lasts 4-7 days. The period of communicability is 1 to 2 days before the onset of rash of fluid filled vesicles up to 7 days after the rash development when all of the vesicles have developed scabs.<sup>31</sup>

Primary infection usually occurs in childhood. Adults are at a much higher risk than children of developing serious complications, which include cerebellar ataxia, encephalitis and bacterial superinfections. Varicella in pregnant women is associated with a risk of intrauterine VZV infection, which might result in congenital varicella syndrome (highest risk during the 13-20 weeks of gestation), neonatal varicella, or herpes zoster during infancy and early childhood.<sup>31</sup>

After primary infection, VZV remains dormant in sensory ganglia. When reactivated, the virus causes HZ (shingles), a painful vesicular rash typically appearing in a dermatomal distribution affecting one or two sensory nerve roots, typically unilaterally. The incidence and severity of HZ is age related, with over 50% of cases occurring in persons over 60 years of age. While patients with HZ may transmit the virus for one week after the lesions erupt, the risk for transmission is much lower than with chicken pox.<sup>32</sup>

**Active Immunization: Varicella Zoster Vaccines.**<sup>4,6</sup>

It is strongly recommended that all OHCP be immune to the VZV. OHCP are considered immune only if they have documentation of:

1. physician-diagnosed varicella (chickenpox) or
2. physician-diagnosed herpes zoster, or
3. laboratory evidence of VZV immunity, or
4. age-appropriate vaccination against the VZV.

There is one monovalent varicella vaccine (*Varivax*) licensed for use in adults (Table 4). It is derived from the Oka strain live attenuated VZV grown sequentially in cultures of human embryonic lung cells, embryonic guinea-pig cells, and human diploid cells. *Zostavax* was a high-potency formulation *Varivax* vaccine (Table 4) that was previously used for HZ prevention. A new adjuvanted recombinant subunit zoster vaccine (*Shingrix*) has superseded *Zostavax* as the vaccine of choice for HZ prevention and is recommended for immunocomprised adults over 19 and immunocompetent adults ≥50 years age. Of note, individuals previously vaccinated with *Zostavax* are recommended to receive *Shingrix* vaccination.<sup>32</sup>

**Passive Immunization: Varicella Zoster Immune Globulin**<sup>4,6</sup>

ACIP recommends<sup>4</sup> that varicella zoster immune globulin (VZIG) be administered within 96 hours of exposure for post-exposure prophylaxis in susceptible persons at high risk for varicella complications. This recommendation applies to women exposed to the VZV at any stage of pregnancy. The VZIG product currently used in the United States is *VariZIG*.

**Table 4.** Varicella Zoster Vaccines.<sup>31,32</sup>

Vaccines	Indications	Schedules	Adverse Effects
<i>Varivax</i>	Preexposure	2 SC doses at least 28 days apart	Injection site or generalized varicella-like rash (1-5%); fever (10%); anaphylaxis.
<i>Shingrix</i>	Prevention of HZ infection in susceptible patients ≥ 50 years old	2 IM doses at 0 and 2-6 months	Myalgia (45%), fatigue (45%), fever (21%), and injection-site pain (78%), redness (38%), and swelling (26%).

### Tetanus, Diphtheria, and Pertussis

Tetanus is a bacterial infection caused by *Clostridium tetani*. The organism is found in soil, dust and animal feces. When *C. tetani* enter a deep wound, its spores produce tetanospasmin, a powerful toxin. Tetanospasmin actively impairs motor neurons. Hallmark manifestations of tetanus include muscle stiffness and spasms in jaw, neck, and abdominal muscles, and difficulty swallowing. Other signs and symptoms may include fever, sweating, elevated blood pressure, and rapid heart rate.<sup>33</sup>

Diphtheria is caused by the bacterium *Corynebacterium diphtheriae*. The organism is transmitted by airborne droplets and contaminated personal and household items. Signs and symptoms usually begin two to five days after a person becomes infected. The hallmark sign of diphtheria is a thick, gray membrane covering the throat and tonsils. Other clinical manifestations may include a sore throat, hoarseness, enlarged lymph nodes, difficulty breathing, nasal discharge, fever, and chills.<sup>34</sup>

Pertussis is a highly contagious bacterial (*Bordetella pertussis*) infection. It is transmitted by direct contact with respiratory secretions or by airborne droplets. The incubation period is about 7 to 10 days. Early symptoms are indistinguishable from those of other respiratory infections. “Hallmark” signs of pertussis are paroxysms (fits) of rapid coughs, followed by a high-pitched “whoop” and vomiting. The period of communicability starts with the early symptoms and extends into the paroxysmal stage.<sup>35</sup>

### Active Immunization: Tetanus, Diphtheria and Pertussis Vaccines<sup>4,6,36</sup>

Vaccine formulations (Table 5) contain either inactivated adsorbed (aluminum-salt-precipitated) tetanus and diphtheria toxoids (Td) or tetanus and diphtheria toxoids and protein components of acellular pertussis (Tdap). OHCP with an uncertain history of primary vaccination should receive an initial dose of Tdap. All OHCP should receive a Td or Tdap booster every 10 years. Tdap is also recommended as part of wound management.<sup>36</sup>

### HPV Infection

HPV, the most common cause of a sexually transmitted infection, is transmitted when the virus enters the body through a cut, abrasion or small tear in the outer layer of skin and genital or oral mucous membranes. Some HPV infections may cause papillomatous, warty lesions on the tongue, tonsils, soft palate, or within the larynx and nose. High-risk HPV strains include HPV 16 and 18, which cause cervical cancer and contribute to cancer in the mouth and upper respiratory tract.<sup>37</sup>

### Active Immunization: HPV Vaccines<sup>4,6,38,3</sup>

A recombinant 9-valent vaccine (*Gardasil 9*) protects against diseases associated with HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, including genital warts and cervical, vulvar, vaginal, and anal precancerous lesions and cancer. On June 12, 2020, *Gardasil 9* was approved for the prevention of oropharyngeal and other head and neck cancers caused by HPV types targeted by the vaccine.<sup>39</sup> It is licensed by the FDA for use in both men and women between 9-45 years of age. The duration of immunity is not known; however, booster doses are not currently recommended.

**Table 5.** Tetanus, Diphtheria and Pertussis Vaccines.<sup>4,6,36</sup>

Vaccines	Indications	Schedules	Adverse Effects
Td <i>Tenivac</i>	Preexposure	1 IM booster dose every 10 years	Injection-site reactions such as pain, swelling, and erythema.
Tdap <i>Adacel</i> <i>Boostix</i>	Preexposure	1 IM booster dose every 10 years	Fever. Arthus-type reactions.

**Table 6.** HPV Vaccines.<sup>38</sup>

Vaccines	Indications	Schedules	Adverse Effects
<i>Gardasil9</i>	Preexposure*	3 IM doses at 0, 1-2, and 6 months	Injection-site reactions such as pain, swelling, and erythema. Potential reaction for those allergic to yeast.  Syncope in adolescents and young adults.

\* Previously unvaccinated females 15 - 26 years old and males 15 - 21 years old should receive a 3-dose series (0, 1-2, and 6 months). Unvaccinated females 27 -45 years old and males 21 - 45 years old should consider vaccination based on behavioral risk for HPV exposure.

**SARS-CoV-2**

SARS-CoV-2, the highly contagious virus that causes COVID-19, is spread predominantly through respiratory droplets produced when an infected person coughs, sneezes, or talks.<sup>40</sup> Symptoms vary widely from mild to severe and include loss of taste or smell, fever, chills, muscle or body aches, sore throat, nausea or vomiting, cough, and breathing difficulties. Symptoms may appear 2-14 days after exposure to the virus; however, some infected patients never develop symptoms and asymptomatic spread is significant.<sup>41,42</sup> The number of deaths in the patient cohort over the age of 65 is 97 times greater than for the patient cohort age 18 - 29.<sup>43</sup> Numerous medical conditions (Box 5) increases one’s risk of developing severe or fatal disease.<sup>43</sup>

**Active Immunization: SARS-CoV-2.<sup>44</sup>**

The first two COVID-19 vaccines (Pfizer-BioNTech [BNT162b2] and Moderna [mRNA-1273]) developed to prevent SARS-CoV-2 infection received Emergency Use Authorizations from the FDA in December 2020 (Table 7). Both vaccines employ the mRNA technology platform and appear to be very efficacious in generating immunity. BNT162b2 is approved for use in persons ≥12 years of age and mRNA-1273 is approved for persons ≥18 years of age. On February 27, 2021, the FDA issued Emergency Use Authorization of the single-dose COVID -19 vaccine (Janssen/Johnson & Johnson) [JNJ-778436735]. It was an adenovirus serotype 26 vector-based vaccine for persons ≥18 years of age and is no longer available in the U.S.<sup>45</sup>

**Box 5.** Conditions Associated with Increased COVID Disease Severity<sup>43</sup>

Cancer	Mental Health Conditions
Chronic Kidney Disease	Overweight and Obesity
Chronic Lung Disease	Physical Inactivity
Cystic Fibrosis	Pregnancy
Dementia	Sickle Cell Disease or Thalassemia
Diabetes (Type 1 or 2)	Smoking ( <i>current or former</i> )
Disabilities	Solid Organ or Blood Stem Cell Transplant
Heart Conditions ( <i>e.g., Heart Failure, Coronary Artery Disease, Cardiomyopathies</i> )	Stroke or Cerebrovascular Disease
HIV	Substance Use Disorder
Immunocompromised Condition	Tuberculosis

The safety of these vaccines for pregnant and breast-feeding women has not been officially established; however, the American College of Obstetricians and Gynecologists recommend otherwise eligible pregnant or lactating women be vaccinated.<sup>44</sup> Other manufacturers (e.g. AstraZeneca/Oxford, Novavax, others worldwide) have developed additional candidate vaccines and approval for children has been granted.

The current recommendation from the CDC is that everyone over 6 months of age get a 2023-2024 dose of one of the three available types of vaccines. For those over 12 years of age, these are the mRNA vaccines Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna), and the subunit protein adjuvanted Novavax COVID-19 vaccine.<sup>46</sup>

### Meningococcal Disease

*Neisseria meningitidis* or *meningococcus* (serogroups A, B, C, Y, and W-135) is a leading cause of bacterial meningitis. The infection is highly contagious and is spread by airborne droplets and contact

with respiratory secretions. Meningococcal meningitis occurs when \*N. meningitidis\* from an upper respiratory tract infection enters the bloodstream and causes inflammation of the meninges surrounding the brain and spinal cord. "Hallmark" signs and symptoms include headache, fever and a stiff neck.<sup>47</sup>

### Active Immunization: Meningococcal Vaccines<sup>4,6,48</sup>

Three quadrivalent vaccines against *N. meningitidis* serogroups A, C, Y, and W0135 two serogroup B meningococcal vaccines, and a pentavalent or Men ABCWY vaccine are available (Table 8). Vaccination is not recommended for an OHCP unless they have a certain risk: 1) asplenia or persistent complement component deficiencies, 2) travel to countries in which meningococcal disease is hyperendemic or epidemic, 3) participate in research OHCP and research microbiologists who might be exposed routinely to isolates of *N. meningitidis*, or 4) any OHCP aged >55 years who have any of the aforementioned risk factors for

**Table 7.** 2023-2024 SARS-CoV-2 Vaccines.<sup>46</sup>

Vaccines	Indications	Schedules	Adverse Effects
Comirnaty	Preexposure	1 IM Dose (at least 4 months after if previously vaccinated against COVID-19)	Injection site pain, erythema and swelling, fatigue, axillary swelling / tenderness, fatigue, chills, headache, fever, muscle and joint pain, rare risk of myocarditis and pericarditis.  Avoid if an allergic reaction to a Pfizer BioNTech COVID-19 vaccine occurred
Spikevax		1 IM Dose (at least 2 months after if previously vaccinated against COVID-19)	Pain at injection site, fatigue, headache, joint and muscle pain, chills, axillary swelling/tenderness and nausea/vomiting. Rare risk of myocarditis and pericarditis.  Avoid if an allergic reaction to a Moderna COVID-19 vaccine occurred.
Novavax COVID-19 Adjuvanted		1 IM Dose if previously vaccinated against COVID-19  2 IM Doses, 0 and 21 days if not previously vaccinated	Injection site pain, erythema and swelling, fatigue, headache, myalgia, fever, nausea/vomiting. Rare risk of myocarditis and pericarditis.  Avoid if an allergic reaction to a Novavax COVID-19 vaccine occurred.

**Table 8.** Meningococcal Vaccines.<sup>48</sup>

Vaccines	Indications	Schedules	Adverse Effects
ACWY <i>Menveo</i> <i>MedQuadfi</i>	Preexposure	1 IM for adults*	Redness, induration, and pain, at the site of injection. Headache, fatigue, and malaise.
Serogroup B <i>Trumenba</i> <i>Bexsero</i>	Preexposure	3 IM doses, 0 1-2, and 6 months.† 2 IM doses, 0 ≥1month.†	Erythema, induration, and pain at the site of injection. Headache, fatigue, and myalgia
MenABCWY <i>Penbraya</i>	Preexposure	2 IM doses, 0, 6 months	Erythema, pain at the site of injection. Headache, fatigue, and myalgia, chills.

\* Revaccination every 3-4 years if risk criteria persist.  
† Single dose boost at 1 year post-initial series and every 2-3 years thereafter if risk criteria persist.

meningococcal disease are recommended for vaccination. A booster can be administered per recommended schedule for any individual at risk. This interval varies for each vaccine.<sup>48</sup>

### Pneumococcal Disease

Most serious pneumococcal infections are caused by *Streptococcus pneumoniae* (pneumococci). There are over 23 known serotypes, but only a few cause most pneumococcal infections. They commonly colonize the respiratory tract and are spread via airborne droplets. Primary infection usually results in otitis media (most common) and pneumonia (most serious). Other pneumococcal infections include sinusitis, meningitis, endocarditis, and septic arthritis. Adults with a compromised immune system and the elderly are at high risk.<sup>49</sup>

### Active Immunization: Pneumococcal Polysaccharide Vaccine.<sup>50</sup>

There are four pneumococcal vaccines: a conjugated vaccine against 13 serotypes (PCV13 [*Prevnar 13*]), a conjugated vaccine against 20 serotypes (PCV20 (*Prevnar 20*)), a conjugated vaccine against 15 serotypes (PCV15 (*Vaxneuvance*)) and a polyvalent polysaccharide vaccine against 23 serotypes (PPSV23

[*Pneumovax 23*]) (Table 9). Current ACIP guidance recommends a single dose of PCV20 alone or PCV13 in series with PPSV23 be administered to all adults ≥65 years of age and adults aged 19-64 with underlying medical conditions or risk factors. The routine use of *Prevnar 13* in adults ≥65 years of age without increased susceptibility is no longer recommended. Instead, shared clinical decision-making for the use of *Prevnar 13* is recommended for these patients. *Prevnar 13* continues to be recommended in series with *Pneumovax 23* for adults at increased susceptibility ≥19 years of age. Persons who received a *Pneumovax 23* vaccine prior to age 65 and those at increased susceptibility should be revaccinated 5 years after the first dose.

### Hepatitis A Viral Infection

The hepatitis A virus (HAV) is primarily transmitted by the fecal-oral route, either by person-to-person contact or consumption of contaminated food or water. It has an incubation period of about 28 days (range: 15–50 days). Among adults the infection is typically symptomatic with fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice. HAV infection is self-limiting and does not result in chronic liver disease.<sup>51</sup>

**Table 9.** Pneumococcal Polysaccharide Vaccine.<sup>4,50</sup>

Vaccines	Indications	Schedules	Adverse Effects
PPSV23 <i>Pneumovax 23</i>	Preexposure	1 IM dose	Injection site erythema, swelling, and pain.
PCV20 <i>Prevnar 20</i>	Preexposure	1 IM dose	Mild to moderate erythema and soreness at the site of injection, fatigue, headache, joint pain.
PCV13 <i>Prevnar 13</i>	Preexposure	1 IM dose	Injection site erythema and swelling at the site of injection.
PCV15 <i>Prevnar 15</i>	Preexposure	1 IM dose	Injection site pain, fatigue, myalgia.

**Active Immunization: Hepatitis A Vaccine**<sup>4,6,52</sup>

There are two inactivated hepatitis A whole-virus vaccines (*Vaqta*, *Havrix*) and a combination hepatitis A and B vaccine (*Twinrix*) available (Table 10). *Twinrix* contains the same hepatitis A component as *Havrix*, but half the dose. Hepatitis A vaccination is recommended for adults who are at high risk for Hepatitis A including individuals with specific health conditions such as chronic liver disease and HIV. In addition, it is recommended for anyone at an increased risk of Hepatitis A such as those who use illicit drugs, men who have sex with men, international travelers, close personal contact to an international adoptee, experiencing homelessness, and those at risk of healthcare-associated exposure. Vaccination with *Vaqta* and *Havrix* consists of 2 doses; vaccination with *Twinrix* requires 3 doses.

**Passive Immunization: Immune Globulin**

Immune globulin is available for short-term pre- and post-exposure protection (approximately 3 months) against hepatitis A. Immune globulin must be administered within 2 weeks after exposure for maximum protection.<sup>6</sup>

**Documenting Immunization Compliance**

An immunization record should be established for each OHCP at the time of initial employment.<sup>4,6,53</sup> The most reliable way to determine immunity is to obtain documentation of:

1. physician-diagnosed infection or
2. laboratory evidence of immunity, or
3. age-appropriate vaccination.

If there is any doubt as to the immune status of an OHCP, it is best to assume that the person is non-immunized. Following each subsequent

**Table 10.** Hepatitis A Vaccines<sup>52</sup>

Vaccines	Indications	Schedules	Adverse Effects
<i>Vaqta</i> <i>Havrix</i>	Pre- and post-exposure	2 IM doses at 0 and 6-18 months 2 IM doses at 0 and 6-12 months	Erythema, edema, pain at injection site; malaise, fever, and fatigue may occur.
<i>Twinrix</i>	Preexposure	3 IM doses at 0, 1, and 6 months	As above plus anaphylaxis in persons with history of allergic reaction to baker's yeast.

immunization encounter, the record should be updated. The information recorded should include the type of vaccine; the dose, route, and site of administration; the name of the person who gave the vaccine; the date the vaccine was given; the manufacturer and lot number; and the date the next dose is due.

A Summary of Infection Prevention Practices in Dental Settings: Basic Expectations for Safe Care was published by the CDC in 2016. This guide is based on elements of Standard Precautions and represents a summary of basic infection prevention expectations for safe care in oral healthcare setting as recommended in the Guidelines for Infection Control in Dental Health-Care Setting – 2003.<sup>48,49</sup> The guide includes an Infection Prevention Checklist for Dental Settings (Appendix A). The Infection Prevention Checklist, Section I: Policies and Practices provides a tool to monitor and document institutional compliance with Dental Health Care Personnel Safety

(Section I.3), i.e., compliance with current CDC recommendations for immunizations.

### Summary

The goal of population-based immunization is to eradicate preventable diseases. The goal of immunization in any one individual, e.g., an oral healthcare provider, is to prevent disease. The decision to immunize OHCP against a specific pathogen is based on:

1. an assessment of the risk of infection,
2. the consequences of natural unmodified illness,
3. the availability of a safe and effective vaccine, and
4. the duration of immunity.

The cost-effectiveness of disease prevention by immunization rather than by disease treatment is unequivocal. This should prompt an acute interest in developing and implementing immunization strategies in all oral healthcare settings.

## Course Test Preview

To receive Continuing Education credit for this course, you must complete the online test. Please go to: [www.dentalcare.com/en-us/ce-courses/ce479/start-test](http://www.dentalcare.com/en-us/ce-courses/ce479/start-test)

### 1. Which statement inaccurately describes vaccine-preventable diseases in the United States?

- A. Immunization programs have markedly reduced vaccine-preventable diseases in children.
- B. Healthcare workers are at a lower risk of vaccine preventable disease than the general public.
- C. Today, a substantial percentage of morbidity and mortality from vaccine-preventable childhood diseases occurs in older adolescents and adults.
- D. Adults who escaped natural infection or immunization during childhood may be at increased risk of vaccine-preventable disease because of advanced age, the presence of certain chronic diseases, or occupation.

### 2. Which of the following is not a characteristic of vaccines?

- A. Whole pathogen vaccines consist of either live-attenuated or inactivated microorganisms.
- B. Subunit vaccines contained fractionated antigenic components of a microorganism.
- C. Vaccines provide immediate immunological protection for the host.
- D. Alum is an example of an adjuvant for generating a sufficient immune response.

### 3. Which description below is not applicable to nucleic acid vaccines?

- A. Provide specific genetic material encoding a target antigen or antigens.
- B. Once introduced, the body's own cells use the genetic material to produce the desired antibody.
- C. These vaccines have increased stability; can be rapidly and inexpensively manufactured.
- D. Potential advantages include no risk of infection and stimulation of broad long-term immunity.

### 4. Neutralizing antibodies readily diffuse into infected cells to interact with the target-organism, while lymphoid K-cells recognize target organisms before initial intracellular penetration.

- A. The first part of the statement is true, but the second part of the statement is false.
- B. The first part of the statement is false, but the second part of the statement is true.
- C. Both parts of the statement are true.
- D. Both parts of the statement are false.

### 5. Which statement inaccurately describes passive immunization?

- A. Previously infected or immunized donors can be the source for passive immunity vaccines.
- B. Passive immunity against specific microorganisms may be conferred with the administration of immunoglobulins.
- C. Passive immunization usually affects an immune response in about 7-10 days.
- D. Useful when active immunization is unavailable, contraindicated, or when an individual cannot form antibodies.

### 6. Which population group should receive live attenuated vaccines?

- A. Pregnant women
- B. Healthy children and adults
- C. Persons with known or suspected congenital or acquired immunodeficiency.
- D. Patients undergoing cancer chemotherapy, post-organ transplantation, and those on corticosteroids



- 7. Which incorrectly describes potential adverse reactions to vaccines?**
- A. Live attenuated vaccines tend to have higher rates of adverse effects.
  - B. The most common allergic component of vaccines is egg proteins found in vaccines prepared in chicken eggs or chicken embryonic cultures.
  - C. Subcutaneous administration of some vaccines, such as those containing aluminum phosphates can lead to local tissue necrosis.
  - D. Intravascular administration tends to reduce adverse effects and increase the immune response.
- 8. Which is not a consideration for immunization strategies for OHCPs?**
- A. Vaccines mandated or strongly recommended at the time of employment.
  - B. Vaccine recommended if another risk factor is presents.
  - C. The availability of immunoglobulins, which are administered to susceptible persons only in the event of inadvertent exposure to blood or OPIM.
  - D. The cost of the vaccine to the employee.
- 9. Which statement is incorrect in relation to the hepatitis B vaccine for the OHCP?**
- A. Hepatitis B viral infection is a minor vaccine preventable health hazard.
  - B. Universal immunization is mandated for all OHCP.
  - C. If declining, they must sign a Mandatory Hepatitis B Vaccination Declination Form.
  - D. Vaccination should be completed during training.
- 10. Which statement inaccurately describes hepatitis B vaccination?**
- A. Consists of two or three IM injections at 0 and 1 month, or 0, 1, and 6 months, respectively.
  - B. Post-vaccination confirmation of seroconversion is mandated 1-2 months after the final dose.
  - C. OHCP with inadequate antibody response shall be offered a second vaccine series.
  - D. If no antibody response occurs to the second hepatitis B vaccination series, testing for HBsAg is strongly recommended.
- 11. Which statement accurately describes the treatment for OHCP who failed to seroconvert following two HBV vaccination series?**
- A. They cannot have patient contact due to an increased risk of HBV infection.
  - B. They should receive an alternate 4-dose series of vaccine if exposed.
  - C. They should receive hepatitis B immune globulin (HBIG) within a week of an exposure.
  - D. They should receive a booster HBV vaccine every 5 years.
- 12. Which is not a recommended approach to influenza prevention?**
- A. OHCP should be vaccinated annually against influenza.
  - B. The virologic basis for the annual influenza vaccine is the emergence of new influenza virus variants.
  - C. The live attenuated intranasal influenza vaccine should be used for individuals >65 years of age.
  - D. Antiviral agents against influenza should be used within 48 hours of symptom onset.
- 13. Which statement incorrectly describes MMR vaccination?**
- A. It is strongly recommended that all OHCP be immune to measles, mumps, and rubella.
  - B. Rubella immunity for women of childbearing age is not a public health recommendation.
  - C. The trivalent MMR vaccine is the vaccine of choice for routine adult vaccination.
  - D. The MMR vaccine contains live attenuated measles, mumps, and rubella viruses.

**14. Which is the least accurate method to confirm immunity to the varicella-zoster virus?**

- A. Physician-diagnosed varicella (chickenpox) or herpes zoster.
- B. Laboratory evidence of VZV immunity.
- C. Age-appropriate vaccination against VZV.
- D. Evidence based on maternal recollection.

**15. Which vaccine is considered the vaccine of choice to prevent shingles (HZ)?**

- A. Varivax
- B. Zostavax
- C. Shingrix
- D. VariZIG

**16. Which statement accurately describes tetanus, diphtheria, and pertussis prevention?**

- A. Tetanus, diphtheria, and pertussis are viral infections.
- B. Tdap vaccine contains tetanus and diphtheria toxoids and acellular pertussis protein.
- C. OHCP should receive initial dose of Tdap followed by an annual booster.
- D. Tdap vaccination is not a recommended component of wound management.

**17. Choose the incorrect statement about Human Papilloma Virus (HPV)**

- A. OHCP may acquire HPV occupationally through mucous membranes or compromised skin.
- B. High-risk strains of HPV may cause cervical cancer and oropharyngeal cancer.
- C. The recommended HPV vaccine for OHCP is the quadrivalent vaccine Gardasil.
- D. Vaccine naïve OHCP <45 years of age deemed at risk for HPV are recommended for vaccination.

**18. Which statement is uncharacteristic of SARS-CoV-2 management?**

- A. There is no risk of spread associated with asymptomatic patients.
- B. It is predominately spread via droplets produced when an infected patient coughs, sneezes, or talks.
- C. Advanced age and certain co-morbidities increases the risk of death from SARS-CoV-2.
- D. Two vaccines received Emergency Use Authorization from the FDA in 2020.

**19. Which statement is inaccurate with respect to Neisseria meningitidis?**

- A. Neisseria meningitidis causes inflammation around the brain and spinal cord.
- B. OHCP who meet certain risk criteria are recommended for vaccination.
- C. All OHCP adults should receive vaccination once they are >55 years of age.
- D. Booster vaccinations are recommended as long as the risk criteria persist.

## References

1. Gardner P, Eickhoff T, Poland GA, et al. Adult immunizations. *Ann Intern Med.* 1996 Jan 1;124(1 Pt 1):35-40.
2. Gardner P, Schaffner W. Immunization of adults. *N Engl J Med.* 1993 Apr 29;328(17):1252-8. doi: 10.1056/NEJM199304293281708.
3. Lu PJ, O'Halloran A, Kennedy ED, et al. Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015. *Vaccine.* 2017 May 25;35(23):3104-3115.
4. Centers for Disease Control (CDC). Vaccine Recommendations and Guidelines of the ACIP. Accessed June 12, 2024.
5. Occupational exposure to bloodborne pathogens--OSHA. Final rule. *Fed Regist.* 1991 Dec 6;56(235):64004-182. Accessed June 12, 2024.
6. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2011 Nov 25;60(RR-7):1-45.
7. National Institute for Allergy and Infectious Diseases. Vaccine Types. Accessed June 12, 2024.
8. National Institute for Allergy and Infectious Diseases. Vaccine Adjuvants. Accessed June 12, 2024.
9. Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. *Nat Rev Drug Discov.* 2018 Apr;17(4):261-279.
10. Kotton CN, Hohmann EL. Enteric pathogens as vaccine vectors for foreign antigen delivery. *Infect Immun.* 2004 Oct;72(10):5535-47.
11. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. *J Allergy Clin Immunol.* 2017 Mar;139(3S):S1-S46.
12. Centers for Disease Control (CDC). National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination. *Morb Mortal Wkly Rep.* 1988 Apr 8;37(13):197-200.
13. Centers for Disease Control and Prevention. Contraindications and Precautions. Accessed June 26, 2024.
14. Eggesbø M, Botten G, Halvorsen R, et al. The prevalence of allergy to egg: a population-based study in young children. *Allergy.* 2001 May;56(5):403-11.
15. Sicherer SH, Sampson HA. 9. Food allergy. *J Allergy Clin Immunol.* 2006 Feb;117(2 Suppl Mini-Primer):S470-5.
16. Savage JH, Matsui EC, Skripak JM, et al. The natural history of egg allergy. *J Allergy Clin Immunol.* 2007 Dec;120(6):1413-7.
17. Centers for Disease Control (CDC). Suboptimal response to hepatitis B vaccine given by injection into the buttock. *MMWR Morb Mortal Wkly Rep.* 1985 Mar 1;34(8):105-8, 113.
18. Centers for Disease Control and Prevention. 2022 Viral Hepatitis Surveillance Report. Accessed June 26, 2024
19. Centers for Disease Control and Prevention. Hepatitis B Information for Health Professionals. Hepatitis B FAQs for Health Professionals. Accessed June 13, 2024
20. *Med Lett Drugs Ther.* 2022 May 16;64(1650):73-5.
21. Durlach R, Laugas S, Freuler CB, Rodriguez VE, Costa M. Ten-year persistence of antibody to hepatitis B surface antigen in healthcare workers vaccinated against hepatitis B virus, and response to booster vaccination. *Infect Control Hosp Epidemiol.* 2003 Oct;24(10):773-6.
22. Centers for Disease Control and Prevention. Influenza (Flu). Information for Health Professionals. Accessed June 26, 2024.
23. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. *MMWR Recomm Rep* 2023;72(No. RR-2):1–25.
24. *Med Lett Drugs Ther.* 2023 Oct 16;65(1687):161-6.
25. *Med Lett Drugs Ther.* 2023 Nov 13;65(1689):177-82.
26. Centers for Disease Control and Prevention. Measles (Rubeola). Accessed June 12, 2024.
27. Centers for Disease Control and Prevention. Mumps. About Mumps. Accessed June 12, 2024.

28. Centers for Disease Control and Prevention. Rubella (German Measles, Three-Day Measles). Accessed June 12, 2024.
29. DeStefano F, Shimabukuro TT. The MMR Vaccine and Autism. *Annu Rev Virol*. 2019 Sep 29;6(1):585-600.
30. Spencer JP, Trondsen Pawlowski RH, Thomas S. Vaccine Adverse Events: Separating Myth from Reality. *Am Fam Physician*. 2017 Jun 15;95(12):786-794.
31. Centers for Disease Control and Prevention. Chickenpox Vaccine (Varicella), What Everyone Should Know. Accessed June 12, 2024.
32. Centers for Disease Control and Prevention. Shingles (Herpes Zoster). About Shingles (Herpes Zoster). Page last updated: May 1, 2014. Accessed June 12, 2024.
33. Centers for Disease Control and Prevention. Tetanus. About Tetanus. Accessed June 13, 2024.
34. Centers for Disease Control and Prevention. Diphtheria. About Diphtheria. Accessed June 13, 2024.
35. Centers for Disease Control and Prevention. Pertussis (Whooping Cough). About Pertussis. Accessed June 13, 2024.
36. Havers FP, Mono PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019. *Morb Mortal Wkly Rep* 2020;69(3):77-83. Accessed June 13, 2024
37. Centers for Disease Control and Prevention. Cancers Caused by HPV Are Preventable. Accessed June 27, 2024.
38. Centers for Disease Control and Prevention. HPV Vaccine Schedule and Dosing. Accessed June 27, 2024.
39. Food and Drug Administration. June 12, 2020 Approval Letter - Gardasil9. Accessed June 26, 2024.
40. Centers for Disease Control and Prevention. How COVID-19 spreads. Accessed June 13, 2024.
41. Centers for Disease Control and Prevention. Symptoms of coronavirus. Accessed June 13, 2024.
42. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. *JAMA Netw Open*. 2021 Jan 4;4(1):e2035057.
43. Centers for Disease Control (CDC). COVID-19. People with Certain Medical Conditions. Accessed June 27, 2024
44. The Medical Letter for Drugs and Therapeutics. Treatments Considered for COVID-19 (Updated April 1, 2022). Accessed June 26, 2024.
45. Centers for Disease Control and Prevention. Janssen (Johnson & Johnson) COVID-19 Vaccine. Accessed June 26, 2024.
46. Center for Disease Control and Prevention. Stay Up to Date with COVID-19 Vaccines. Accessed June 13, 2024.
47. Centers for Disease Control and Prevention. Meningococcal Disease. Accessed June 26, 2024.
48. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recomm Rep* 2020;69(RR-9):1-41
49. Centers for Disease Control and Prevention. Pneumococcal Disease. Accessed June 26, 2024.
50. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. *MMWR Recomm Rep* 2023;72(No. RR-3):1-39.
51. Centers for Disease Control and Prevention. Clinical Overview of Hepatitis A. Accessed June 14, 2024.
52. Centers for Disease Control and Prevention. Hepatitis A Vaccine Administration. Accessed Jun 27, 2024.
53. Kohn WG, Collins AS, Cleveland JL, et al. Guidelines for Infection Control in Dental Health-Care Settings — 2003. *MMWR Recomm Rep* 2003;52(RR-17):1-76. Accessed June 27, 2024.
54. Centers for Disease Control and Prevention. Summary of Infection Prevention Practices in Dental Settings: Basic Expectations for Safe Care. Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; October 2016. Accessed June 27, 2024.

## About the Authors

### Michael A. Huber, DDS



Dr. Michael A. Huber is a 1980 graduate from the University of Texas Health Science Center at San Antonio Dental School, San Antonio, Texas. Upon graduation, he embarked upon 22-year career serving in the United States Navy Dental Corps. He received a Certificate in Oral Medicine from the National Naval Dental Center, Bethesda, Maryland in 1988 and is diplomate of the American Board of Oral Medicine. From 1996-1998, he served as Chairman, Department of Oral Medicine and Maxillofacial Radiology; Director, Graduate Program in Oral Medicine, National Naval Dental Center, Bethesda, Maryland; and as Specialty Leader for Oral Medicine to the Surgeon General of the United States Navy, Washington, DC. In 2002, Dr. Huber returned to his alma mater to teach both pre-doctoral and graduate dental students. He is a recipient of the 2014 UTHSCSA Presidential Teaching Excellence Award, the 2018 Diamond Pin Award from the American Academy of Oral Medicine, and the 2019 UT Regents Outstanding Teaching Award. He is a Past President of the American Academy of Oral Medicine. Dr. Huber retired from his full-time faculty position in the summer of 2020, but continues to support the School of Dentistry's mission of teaching excellence as an Adjunct Professor. He is a member of the dentalcare.com Advisory Board and currently serves as a member of the National Commission on Recognition of Dental Specialties and Certifying Boards.

Email: [huberm@uthscsa.edu](mailto:huberm@uthscsa.edu)

### Denise Kissell, BSDH, EFDA, MPH



Denise Kissell, BSDH, EFDA, MPH, is an Associate Clinical Professor at The Ohio State University College of Dentistry. Ms. Kissell received her Bachelor of Science in Dental Hygiene and her Master of Public Health degrees from The Ohio State University. She accepted a full-time faculty position in 2006, and directs courses for baccalaureate dental hygiene students, graduate dental hygiene students, and dental students. In addition, she is a practicing dental hygienist at the OSU Dental Faculty Practice and teaches continuing education courses for oral health professionals in the community. She serves as a member on national dental hygiene committees, including test construction committees for the National Board Dental Hygiene Examination (NBDHE)

Email: [kissell.22@osu.edu](mailto:kissell.22@osu.edu)

### Géza T. Terézhalmy, DDS, MA



Dr. Terézhalmy is Professor and Dean Emeritus, School of Dental Medicine, Case Western Reserve University. Dr. Terézhalmy earned a BS degree from John Carroll University; a DDS degree from Case Western Reserve University; an MA in Higher Education and Human Development from The George Washington University; and a Certificate in Oral Medicine from the National Naval Dental Center. Over the past 50+ years, Dr. Terézhalmy held more than 30 positions in professional societies, served as editor or contributing editor for several publications, co-authored or contributed chapters for several books, conducted oral healthcare related research, and had over 250 papers and abstracts published.

Email: [gterezhalm@gmail.com](mailto:gterezhalm@gmail.com)